---
title: "This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291148602.md"
description: "Wall Street analysts downgraded five stocks on Monday. B of A's Allen Lutz downgraded Doximity (DOCS) to Underperform with a $20 target. Jason Gerberry downgraded Amphastar (AMPH) to Underperform ($20 target), Liquidia (LQDA) to Neutral ($79 target), and Alkermes (ALKS) to Underperform ($38 target). Seaport Global's David Joyce downgraded Madison Square Garden Entertainment (MSGE) to Neutral."
datetime: "2026-06-29T12:49:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291148602.md)
  - [en](https://longbridge.com/en/news/291148602.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291148602.md)
---

# This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

-   B of A Securities analyst Allen Lutz downgraded **Doximity Inc** (NYSE:DOCS) from Buy to Underperform and cut the price target from $38 to $20. Doximity shares closed at $20.88 on Friday. See how other analysts view this stock.
-   B of A Securities analyst Jason Gerberry downgraded **Amphastar Pharmaceuticals, Inc** (NASDAQ:AMPH) from Neutral to Underperform and lowered the price target from $25 to $20. Amphastar Pharma shares closed at $21.78 on Friday. See how other analysts view this stock.
-   Seaport Global analyst David Joyce downgraded **Madison Square Garden Entertainment Corp** (NYSE:MSGE) from Buy to Neutral. Madison Square Garden shares closed at $80.30 on Friday. See how other analysts view this stock.
-   B of A Securities analyst Jason Gerberry downgraded **Liquidia Corp** (NASDAQ:LQDA) from Buy to Neutral and raised the price target from $64 to $79. Liquidia shares closed at $78.17 on Friday. See how other analysts view this stock.
-   B of A Securities analyst Jason Gerberry downgraded **Alkermes Plc** (NASDAQ:ALKS) from Neutral to Underperform and announced a $38 price target. Alkermes shares closed at $55.08 on Friday. See how other analysts view this stock.

Considering buying LQDA stock? Here’s what analysts think:

_Photo via Shutterstock_

### Related Stocks

- [DOCS.US](https://longbridge.com/en/quote/DOCS.US.md)
- [LQDA.US](https://longbridge.com/en/quote/LQDA.US.md)
- [ALKS.US](https://longbridge.com/en/quote/ALKS.US.md)
- [MSGE.US](https://longbridge.com/en/quote/MSGE.US.md)
- [AMPH.US](https://longbridge.com/en/quote/AMPH.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [Doximity, Inc. (NYSE:DOCS) Given Consensus Recommendation of "Hold" by Brokerages](https://longbridge.com/en/news/294173072.md)
- [Liquidia (NASDAQ:LQDA) Director Sells $286,061.80 in Stock](https://longbridge.com/en/news/294177816.md)
- [Liquidia (NASDAQ:LQDA) Insider Sells $60,220.64 in Stock](https://longbridge.com/en/news/294262726.md)
- [This Analyst Just Cut Its Price Target on SNDK Stock. Here's Why.](https://longbridge.com/en/news/293654906.md)
- [LifeSci Capital Sticks to Their Buy Rating for Liquidia Technologies (LQDA)](https://longbridge.com/en/news/293825271.md)